#United States #New York #Securities Fraud #Wolf Haldenstein #Inspire Medical

Urgent Call to Action for Inspire Medical Systems Investors

In the wake of troubling developments at Inspire Medical Systems, Inc. (NYSE: INSP), shareholders who experienced financial loss are being urged to reach out to legal experts at Wolf Haldenstein Adler Freeman & Herz LLP. The firm has already initiated a securities class action to represent those who bought shares between August 6, 2024, and August 4, 2025.

Background of the Case

The litigation stems from allegations that Inspire Medical and certain executives misled investors regarding the launch and performance of the Inspire V sleep apnea device. This includes serious claims that essential information about the device's market entry was either distorted or concealed, leading to significant financial harm for shareholders.

On August 4, 2025, Inspire disclosed critical setbacks that played a role in the decline of its stock value. The firm reported major delays in training and onboarding personnel at various medical centers, which directly affected the rollout of the Inspire V. Additionally, although the device secured a CPT code for Medicare billing, processing was stalled due to necessary software updates only being implemented on July 1, 2025. This further complicated reimbursement, leading many centers to continue using the older Inspire IV device instead.

Significant Financial Impact

The impact of these issues was stark. Inspire drastically reduced its earnings guidance by more than 80%—from a range of $2.20–$2.30 per share to only $0.40–$0.50. Consequently, the company's stock plummeted over 32% in just one day—dropping from a closing price of $129.95 on August 4 to $87.91 the following day. This dramatic decrease wiped an estimated $1.2 billion off the company's market capitalization in just one trading session. To illustrate, from a high of $216.71 per share on September 23, 2024, the stock fell nearly 60%, resulting in losses amounting to billions for shareholders.

Deadline for Legal Action

Investors who suffered losses due to these events must act quickly, as the deadline to seek appointment as lead plaintiff is January 5, 2026. Wolf Haldenstein, with an impressive history of over 125 years in securities litigation, remains dedicated to securing justice for affected individuals.

Why Contact Wolf Haldenstein?

Wolf Haldenstein Adler Freeman & Herz LLP is renowned for its commitment to investor rights and has a proven track record in winning significant settlements and verdicts on behalf of shareholders. The firm's dedication and expertise ensure that investors affected by Inspire Medical's misrepresentations have a strong advocate in their corner.

If you purchased shares or have any relevant information regarding the Inspire situation, the legal team at Wolf Haldenstein invites you to contact them. You may reach out via phone at (800) 575-0735 or (212) 545-4774 and can also send inquiries to their email at [email protected] The case may be evolving, but the window for action is rapidly closing. Don’t miss your chance to seek justice!

Conclusion

It is crucial for those impacted by the Inspire Medical situation to stay informed and proactive. Contact Wolf Haldenstein today to explore your legal options and be part of the movement to hold companies accountable for their actions. Your rights as an investor are paramount, and standing up against fraud is the first step towards safeguarding your financial future.